Cover Image
市場調查報告書

Domain Therapeutics SA的產品平台分析

Domain Therapeutics SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319971
出版日期 內容資訊 英文 32 Pages
訂單完成後即時交付
價格
Back to Top
Domain Therapeutics SA的產品平台分析 Domain Therapeutics SA - Product Pipeline Review - 2015
出版日期: 2015年09月30日 內容資訊: 英文 32 Pages
簡介

Domain Therapeutics SA是總公司設置於法國的製藥企業,正在進行以神經性,神經精神系,發炎,代謝疾病,癌症等廣泛疾病為對象,G蛋白質共軛受體(GPCR)為標的之候補化合物的藥物研發。開發中產品有GPR88,mGluR2 PAM(對象疾病:思覺失調症),mGluR3 NAM(對象疾病:癌症),mGluR3 PAM, mGluR4 PAM(對象疾病:老年癡呆症),A2Aantagonist(對象疾病:帕金森氏症)等。

本報告提供Domain Therapeutics SA的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Domain Therapeutics SA的基本資料

  • Domain Therapeutics SA概要
  • 主要資訊
  • 企業資料

Domain Therapeutics SA:R&D概要

  • 主要的治療範圍

Domain Therapeutics SA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Domain Therapeutics SA:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Domain Therapeutics SA:藥物簡介

  • DT-010709
  • DT-0926
  • DT-1133
  • DT-2442
  • DT-010991
  • Small Molecule to Activate Metabotropic Glutamate Receptor 2 for Schizophrenia
  • Small Molecule to Target GPR88 for Schizophrenia
  • Small Molecules to Target GPCR for Undisclosed Indication

Domain Therapeutics SA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Domain Therapeutics SA:最新的開發平台資訊

Domain Therapeutics SA:開發被休止了的計劃

Domain Therapeutics SA:總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07600CDB

Summary

Global Markets Direct's, 'Domain Therapeutics SA - Product Pipeline Review - 2015', provides an overview of the Domain Therapeutics SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Domain Therapeutics SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Domain Therapeutics SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Domain Therapeutics SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Domain Therapeutics SA's pipeline products

Reasons to buy

  • Evaluate Domain Therapeutics SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Domain Therapeutics SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Domain Therapeutics SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Domain Therapeutics SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Domain Therapeutics SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Domain Therapeutics SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Domain Therapeutics SA Snapshot
    • Domain Therapeutics SA Overview
    • Key Information
    • Key Facts
  • Domain Therapeutics SA - Research and Development Overview
    • Key Therapeutic Areas
  • Domain Therapeutics SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Domain Therapeutics SA - Pipeline Products Glance
    • Domain Therapeutics SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • Domain Therapeutics SA - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Domain Therapeutics SA - Drug Profiles
    • DT-010709
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DT-2442
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize Adenosine A2A Receptor for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize GPR88 for Attention Deficit Hyperactivity Disorder and Schizophrenia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Antagonize mGluR2 for Parkinson's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DT-010991
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target GPCR for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Domain Therapeutics SA - Pipeline Analysis
    • Domain Therapeutics SA - Pipeline Products by Target
    • Domain Therapeutics SA - Pipeline Products by Route of Administration
    • Domain Therapeutics SA - Pipeline Products by Molecule Type
    • Domain Therapeutics SA - Pipeline Products by Mechanism of Action
  • Domain Therapeutics SA - Recent Pipeline Updates
  • Domain Therapeutics SA - Dormant Projects
  • Domain Therapeutics SA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Domain Therapeutics SA, Key Information
  • Domain Therapeutics SA, Key Facts
  • Domain Therapeutics SA - Pipeline by Indication, 2015
  • Domain Therapeutics SA - Pipeline by Stage of Development, 2015
  • Domain Therapeutics SA - Monotherapy Products in Pipeline, 2015
  • Domain Therapeutics SA - Partnered Products in Pipeline, 2015
  • Domain Therapeutics SA - Partnered Products/ Combination Treatment Modalities, 2015
  • Domain Therapeutics SA - Out-Licensed Products in Pipeline, 2015
  • Domain Therapeutics SA - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Domain Therapeutics SA - Preclinical, 2015
  • Domain Therapeutics SA - Discovery, 2015
  • Domain Therapeutics SA - Unknown, 2015
  • Domain Therapeutics SA - Pipeline by Target, 2015
  • Domain Therapeutics SA - Pipeline by Route of Administration, 2015
  • Domain Therapeutics SA - Pipeline by Molecule Type, 2015
  • Domain Therapeutics SA - Pipeline Products by Mechanism of Action, 2015
  • Domain Therapeutics SA - Recent Pipeline Updates, 2015
  • Domain Therapeutics SA - Dormant Developmental Projects,2015
  • Domain Therapeutics SA, Subsidiaries

List of Figures

  • Domain Therapeutics SA - Pipeline by Top 10 Indication, 2015
  • Domain Therapeutics SA - Pipeline by Stage of Development, 2015
  • Domain Therapeutics SA - Monotherapy Products in Pipeline, 2015
  • Domain Therapeutics SA - Out-Licensed Products in Pipeline, 2015
  • Domain Therapeutics SA - Pipeline by Top 10 Target, 2015
  • Domain Therapeutics SA - Pipeline by Top 10 Molecule Type, 2015
  • Domain Therapeutics SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top